39.jpg)
In a significant development for Indian patients requiring treatment for structural or congenital heart disease and defects, Admedus in partnership with Syncronei Medical India and supported by the Australian Trade and Investment Commission (Austrade) has now launched its clinically-superior Adapt technology in the country.
From 30 January 2018, physicians in India will have access to the transformative power and significant patient benefits of Adapt engineered tissue and Admedus’ flagship product CardioCel, a bio-scaffold for the management of congenital and adult structural heart abnormalities.
“In a country with approximately 50 million cardiac patients and 2,80,000 babies born annually with a Congenital Heart Defect (CHD), the introduction of our disruptive Adapt technology is a significant opportunity for India’s physicians to provide life-changing outcomes for their patients,” said Wayne Paterson, CEO, Admedus.
“CardioCel has been available in North America and Europe for some time but this is the first time Indian physicians and patients have had access to Admedus’ world-class Adapt technology,” he added.
Adapt is primarily used in restorative structural heart repair and reconstruction. It has helped to treat the heart tissue which provides resistance to calcification, delivering transformative repair with long-term durability that enables native cells to successfully grow and differentiate through the entire repair, without calcification or toxicity.
“Our clinically superior Adapt products, invented and manufactured in our state-of-the-art manufacturing facility in Australia, are the only ones to have achieved nine years without calcification or degradation, providing Indian surgeons with a potential lifetime solution for their patients,” stated Paterson.
To support the launch of CardioCel in India, Adapt inventor and Professor Leon Neethling, Vice President, Cardiovascular Technologies Admedus will deliver a comprehensive series of meetings and presentations with physicians in major health centres across India to demonstrate the product’s clinical applications and benefits.
Syncronei is appointed as exclusive commercial partner managing all sales, marketing and distribution.
Both Admedus and Syncronei Medical are looking forward to working closely with Indian clinicians, health officials and key opinion leaders (KOLs) to build productive long-term relationships focused on helping to improve the health outcomes and quality of life for Indian patients with heart disease.
Admedus launches adapt technology, syncronei medical india, treatment of congenital heart disease
2.jpg)
6.png)